ABSTRACT
PURPOSE: Hydration is needed before and after cisplatin infusion for reducing the risk of nephrotoxicity. Even though there is no standard regimen, patients receive mostly intravenous hydration before and after cisplatin leading hospitalization during at least one night. Since the feasibility has been published, oral hydration after cisplatin was implemented in our practice. The safety of this new way of hydration needs to be assessed in clinical practice. METHODS: We collected medical records from patients treated by cisplatin for lung cancer in our unit between 2010 and 2016. We retrospectively analyzed the incidence of cisplatin induced nephrotoxicity between after and before the change of hydration regimen. RESULTS: Our patient cohort included 241 patients hydrated by intravenous regimen (IV/IV group) and 276 patient hydrated by intravenous and oral regimen (IV/PO group). Grade ≥ 1 nephrotoxicity occurred in 39.4 and 25.7% in the IV/IV and IV/PO groups respectively (p = 0.001). Age over 70 at baseline was a predictive factor for nephrotoxicity, but not estimated glomerular filtration rate nor cisplatin-associated drugs. After a multivariate analysis, age remained a predictive factor for nephrotoxicity and IV/PO hydration associated with a decrease in nephrotoxic risk. CONCLUSION: The implementation of oral hydration in our practice was not associated with an increase in nephrotoxicity. Our observation based on large data from clinical practice shows that oral hydration after cisplatin is safe.
Subject(s)
Cisplatin/administration & dosage , Cisplatin/adverse effects , Fluid Therapy/adverse effects , Fluid Therapy/methods , Kidney Diseases/chemically induced , Kidney Diseases/prevention & control , Lung Neoplasms/therapy , Adult , Aged , Aged, 80 and over , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/adverse effects , Cohort Studies , Female , Glomerular Filtration Rate/drug effects , Humans , Incidence , Infusions, Intravenous , Lung Neoplasms/drug therapy , Male , Middle Aged , Retrospective Studies , Young AdultABSTRACT
A 30-item self-completed survey was administered to 216 consecutive patients with various movement disorders in order to assess their knowledge base, perceptions, and beliefs about brain donation. Two hundred three surveys were analyzed. While 78% of study participants did not know about brain donation before completing the survey, 56% would be willing to consider brain donation. Willingness to consider brain donation is not significantly different between genders, or influenced by the degree of religious involvement, marital status, or disease duration. Majority of the study participants consider discussions about brain donation appropriate during regular clinic visits. Younger participants were more likely to consider brain donation. Major motivating factors to pursue brain donation were advancement of medical knowledge, providing hope and purpose for others, and advancing our understanding of hereditability of a disorder that may impact surviving family members. We advocate proactive education of patients with various movement disorders about the purpose and benefits of brain donation.
Subject(s)
Attitude to Health , Brain , Emotions , Movement Disorders/psychology , Tissue Donors/psychology , Adolescent , Adult , Aged , Cohort Studies , Emotions/physiology , Female , Health Surveys , Humans , Male , Middle Aged , Surveys and Questionnaires , Young AdultABSTRACT
Recent data suggests that isradipine, a dihydropyridine calcium channel blocker, is neuroprotective in preclinical models of parkinsonism. Isradipine has not been systematically studied in patients with Parkinson's disease (PD). The aim of this study was to evaluate safety and tolerability of isradipine controlled release (CR) in patients with early PD. Qualified subjects (n = 31) received isradipine CR, titrated from 5 to 20 mg daily dose over 8 weeks as tolerated. Eighty-one percent of subjects completed the study. Tolerability of isradipine CR was dose dependent: 94% for 5 mg dose; 87% for 10 mg; 68% for 15 mg; and 52% for 20 mg. Isradipine had no significant effect on blood pressure or PD motor disability. The two most common reasons for dose reduction were leg edema (7) and dizziness (3). There was no difference in isradipine tolerability between subjects with and without dopaminergic treatment, or with and without hypertension.
